Loading...

ArQule

DB:AQL
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AQL
DB
$713M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print
  • ArQule has significant price volatility in the past 3 months.
AQL Share Price and Events
7 Day Returns
14.8%
DB:AQL
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
142%
DB:AQL
-10.2%
DE Biotechs
-6%
DE Market
AQL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ArQule (AQL) 14.8% 24.2% 72.3% 142% 246.8% 386.5%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • AQL outperformed the Biotechs industry which returned -10.2% over the past year.
  • AQL outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
AQL
Industry
5yr Volatility vs Market

AQL Value

 Is ArQule undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ArQule to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ArQule.

DB:AQL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:AQL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (2.07%))
1.316
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.32
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.316 * 5.96%)
8.07%

Discounted Cash Flow Calculation for DB:AQL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ArQule is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:AQL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.07%)
2019 -38.20 Analyst x1 -35.35
2020 -24.37 Analyst x2 -20.86
2021 27.45 Analyst x2 21.75
2022 19.42 Analyst x2 14.24
2023 77.55 Analyst x2 52.61
2024 121.08 Est @ 56.13% 76.01
2025 168.75 Est @ 39.36% 98.01
2026 215.36 Est @ 27.62% 115.75
2027 257.14 Est @ 19.4% 127.89
2028 292.25 Est @ 13.65% 134.49
Present value of next 10 years cash flows $584.53
DB:AQL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $292.25 × (1 + 0.23%) ÷ (8.07% – 0.23%)
$3,735.05
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,735.05 ÷ (1 + 8.07%)10
$1,718.83
DB:AQL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $584.53 + $1,718.83
$2,303.36
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,303.36 / 109.10
$21.11
DB:AQL Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:AQL represents 0.85107x of NasdaqGM:ARQL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.85107x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 21.11 x 0.85107
€17.97
Value per share (EUR) From above. €17.97
Current discount Discount to share price of €5.57
= -1 x (€5.57 - €17.97) / €17.97
69%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price ArQule is available for.
Intrinsic value
>50%
Share price is €5.57 vs Future cash flow value of €17.97
Current Discount Checks
For ArQule to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • ArQule's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • ArQule's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ArQule's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ArQule's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AQL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.16
NasdaqGM:ARQL Share Price ** NasdaqGM (2019-04-18) in USD $6.54
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ArQule.

DB:AQL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ARQL Share Price ÷ EPS (both in USD)

= 6.54 ÷ -0.16

-41.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ArQule is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ArQule is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ArQule's expected growth come at a high price?
Raw Data
DB:AQL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -41.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
49%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ArQule, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ArQule's assets?
Raw Data
DB:AQL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.72
NasdaqGM:ARQL Share Price * NasdaqGM (2019-04-18) in USD $6.54
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:AQL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ARQL Share Price ÷ Book Value per Share (both in USD)

= 6.54 ÷ 0.72

9.03x

* Primary Listing of ArQule.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ArQule is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ArQule's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ArQule has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AQL Future Performance

 How is ArQule expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
49%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ArQule expected to grow at an attractive rate?
  • ArQule's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • ArQule's earnings growth is expected to exceed the Germany market average.
  • ArQule's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:AQL Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AQL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 49%
DB:AQL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 41.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AQL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AQL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 168 74 87 2
2022-12-31 91 108 -2 2
2021-12-31 44 34 -11 3
2020-12-31 15 -27 -34 5
2019-12-31 4 -42 -42 5
DB:AQL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 26 -13 -15
2018-09-30 23 -12 -15
2018-06-30 18 -12 -16
2018-03-31 4 -22 -28
2017-12-31 -25 -29
2017-09-30 1 -27 -28
2017-06-30 2 -27 -27
2017-03-31 3 -25 -25
2016-12-31 5 -23 -23
2016-09-30 6 -21 -19
2016-06-30 8 -20 -15
2016-03-31 10 -21 -14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ArQule's earnings are expected to grow significantly at over 20% yearly.
  • ArQule's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AQL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from ArQule Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AQL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.70 0.95 0.45 2.00
2022-12-31 -0.04 0.27 -0.31 3.00
2021-12-31 -0.09 0.15 -0.43 3.00
2020-12-31 -0.29 -0.19 -0.43 5.00
2019-12-31 -0.37 -0.37 -0.38 5.00
DB:AQL Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.16
2018-09-30 -0.16
2018-06-30 -0.19
2018-03-31 -0.36
2017-12-31 -0.39
2017-09-30 -0.40
2017-06-30 -0.39
2017-03-31 -0.36
2016-12-31 -0.33
2016-09-30 -0.28
2016-06-30 -0.23
2016-03-31 -0.22

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ArQule will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ArQule's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ArQule has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AQL Past Performance

  How has ArQule performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ArQule's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ArQule does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare ArQule's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ArQule's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ArQule's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ArQule Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AQL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 25.76 -15.48 10.75
2018-09-30 22.82 -14.76 9.86
2018-06-30 17.84 -15.80 8.20
2018-03-31 4.14 -28.16 7.83
2017-12-31 -29.20 7.55
2017-09-30 1.19 -28.26 7.51
2017-06-30 2.41 -27.41 7.57
2017-03-31 3.48 -25.31 7.59
2016-12-31 4.71 -22.72 7.56
2016-09-30 6.32 -18.75 7.78
2016-06-30 7.75 -15.29 7.80
2016-03-31 9.68 -14.20 8.69
2015-12-31 11.24 -13.77 9.83
2015-09-30 11.46 -14.43 10.64
2015-06-30 11.47 -18.48 11.80
2015-03-31 11.36 -20.80 12.09
2014-12-31 11.25 -23.39 12.15
2014-09-30 10.51 -25.84 12.44
2014-06-30 11.39 -25.52 12.56
2014-03-31 12.93 -25.97 12.69
2013-12-31 15.91 -24.60 12.84
2013-09-30 18.78 -23.94 13.06
2013-06-30 26.18 -18.29 13.34
2013-03-31 33.58 -12.39 13.65
2012-12-31 36.41 -10.87 13.85
2012-09-30 47.78 -1.81 16.52
2012-06-30 48.79 -3.64 16.26

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ArQule has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ArQule has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ArQule improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ArQule's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ArQule has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AQL Health

 How is ArQule's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ArQule's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ArQule is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ArQule's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ArQule's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 7.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ArQule Company Filings, last reported 3 months ago.

DB:AQL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 78.97 14.76 99.56
2018-09-30 87.10 14.68 100.18
2018-06-30 27.24 14.60 46.08
2018-03-31 22.32 14.52 42.88
2017-12-31 24.54 14.61 48.04
2017-09-30 6.06 14.52 27.60
2017-06-30 10.09 14.43 31.01
2017-03-31 16.99 14.34 37.54
2016-12-31 23.68 0.00 31.13
2016-09-30 30.08 0.00 37.66
2016-06-30 35.48 0.00 43.12
2016-03-31 40.12 0.00 47.64
2015-12-31 29.18 0.00 38.77
2015-09-30 31.44 0.00 43.76
2015-06-30 33.28 0.00 48.00
2015-03-31 36.82 0.00 53.58
2014-12-31 40.55 0.00 59.21
2014-09-30 43.41 1.70 62.09
2014-06-30 49.06 1.70 63.20
2014-03-31 54.55 1.70 71.73
2013-12-31 60.63 1.70 74.70
2013-09-30 65.78 1.70 82.26
2013-06-30 70.94 1.70 80.10
2013-03-31 76.63 1.70 87.11
2012-12-31 81.03 1.70 79.27
2012-09-30 85.37 1.70 82.76
2012-06-30 84.23 1.70 75.09
  • ArQule's level of debt (18.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (2.8% vs 18.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ArQule has sufficient cash runway for more than 3 years based on current free cash flow.
  • ArQule has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -13.1% each year.
X
Financial health checks
We assess ArQule's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ArQule has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AQL Dividends

 What is ArQule's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ArQule dividends.
If you bought €2,000 of ArQule shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ArQule's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ArQule's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AQL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AQL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ArQule has not reported any payouts.
  • Unable to verify if ArQule's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ArQule's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ArQule has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ArQule's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ArQule afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ArQule has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AQL Management

 What is the CEO of ArQule's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paolo Pucci
COMPENSATION $1,744,527
AGE 57
TENURE AS CEO 10.8 years
CEO Bio

Mr. Paolo Pucci has been Chief Executive Officer of ArQule Inc. since June 2008. Prior to joining ArQule in 2008, Mr. Pucci served as the President of Global Specialty Business Unit and Senior Vice President of Bayer HealthCare LLC of Bayer Corporation where he served as President in charge of the Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics Business Units. He served as Senior Vice President of Bayer Pharmaceuticals Global Specialty Business Unit, President of U.S. Pharmaceutical Operations and a member of the Bayer Pharmaceuticals Global Management Committee. Mr. Pucci was involved in a broad range of activities related to Nexavar® (sorafenib), an oral multiple kinase inhibitor to treat liver and kidney cancers. He joined Bayeras head of its Italian Pharmaceutical operations in 2001. He held positions of increasing responsibility with Eli Lilly, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. At Lilly, his responsibilities included operations, sales, marketing and strategic planning. He has been a Director of West Pharmaceutical Services, Inc. since September 12, 2016, Algeta ASA since April 2013 and ArQule Inc. since June 2008. He was a Director of NewLink Genetics Corporation since November 13, 2015 until October 31, 2018. He served as a Director at Dyax Corp. from November 2011 to January 22, 2016. Mr. Pucci holds an MBA from the University of Chicago and is a graduate of the Universita Degli Studi Di Napoli in Naples, Italy.

CEO Compensation
  • Paolo's compensation has increased whilst company is loss making.
  • Paolo's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the ArQule management team in years:

4.6
Average Tenure
56
Average Age
  • The tenure for the ArQule management team is about average.
Management Team

Paolo Pucci

TITLE
CEO & Director
COMPENSATION
$2M
AGE
57
TENURE
10.8 yrs

Peter Lawrence

TITLE
President
COMPENSATION
$1M
AGE
55
TENURE
11 yrs

Brian Schwartz

TITLE
Chief Medical Officer & Senior VP
COMPENSATION
$1M
AGE
56
TENURE
10.8 yrs

Marc Schegerin

TITLE
CFO, Head of Strategy & Treasurer
TENURE
0.1 yrs

Blaine Schamber

TITLE
Principal Accounting Officer
TENURE
0.1 yrs

Dawn Schottlandt

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
3.8 yrs

Deb Wall

TITLE
Senior Manager of Human Resources
TENURE
4.6 yrs
Board of Directors Tenure

Average tenure and age of the ArQule board of directors in years:

14.3
Average Tenure
65.5
Average Age
  • The average tenure for the ArQule board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Pat Zenner

TITLE
Chairman
COMPENSATION
$110K
AGE
71
TENURE
14.9 yrs

Paolo Pucci

TITLE
CEO & Director
COMPENSATION
$2M
AGE
57
TENURE
10.8 yrs

Tim Barabe

TITLE
Independent Director
COMPENSATION
$92K
AGE
65
TENURE
17.4 yrs

Chiang Li

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
$806K
AGE
53
TENURE
12.3 yrs

William Messenger

TITLE
Independent Director
COMPENSATION
$97K
AGE
57
TENURE
14.3 yrs

Ronald Lindsay

TITLE
Independent Director
COMPENSATION
$106K
AGE
70
TENURE
13.8 yrs

Werner Cautreels

TITLE
Member of Scientific Advisory Board
COMPENSATION
$8K
AGE
66

Bob Weinberg

TITLE
Member of Scientific Advisory Board

Dan Von Hoff

TITLE
Member of Scientific Advisory Board
AGE
70
TENURE
14.8 yrs

Arthur Pardee

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
22. Oct 18 Buy Pontifax Ltd. Company 13. Jul 18 13. Jul 18 181,818 €4.71 €856,899
01. Jun 18 Sell BVF Partners LP Company 30. May 18 30. May 18 -1,035,939 €4.30 €-4,452,555
22. May 18 Buy Ran Nussbaum Individual 18. May 18 18. May 18 8,611 €2.80 €24,072
18. May 18 Buy Paolo Pucci Individual 18. May 18 18. May 18 15,000 €2.88 €43,206
15. May 18 Buy Patrick Zenner Individual 14. May 18 14. May 18 8,446 €2.47 €20,876
15. May 18 Buy Ronald Lindsay Individual 11. May 18 11. May 18 6,900 €2.26 €15,574
11. May 18 Buy Paolo Pucci Individual 10. May 18 10. May 18 1,300 €2.22 €2,881
11. May 18 Buy Ronald Lindsay Individual 10. May 18 10. May 18 23,900 €2.25 €53,668
X
Management checks
We assess ArQule's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ArQule has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AQL News

Simply Wall St News

AQL Company Info

Description

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company’s pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton’s tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company’s pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.

Details
Name: ArQule, Inc.
AQL
Exchange: DB
Founded: 1993
$633,718,499
109,095,759
Website: http://www.arqule.com
Address: ArQule, Inc.
One Wall Street,
Burlington,
Massachusetts, 01803,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ARQL Common Shares Nasdaq Global Market US USD 16. Oct 1996
DB AQL Common Shares Deutsche Boerse AG DE EUR 16. Oct 1996
Number of employees
Current staff
Staff numbers
36
ArQule employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 20:34
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.